|
Siemens filed the initial mdr 1219913-2019-00169 on september 30, 2019.Siemens filed the mdr 1219913-2019-00169 supplemental report 1 on march 05, 2020.April 29, 2020 additional information: siemens reviewed siemens remote solution (srs) worldwide from february 2019 - march 2020 with 13 reagent lots of data.All ous lots: 272, 275, 277, 278 , 279, 281, 284, 286.N : 28,160, 327,575, 275,872, 103,717, 78,779, 9,421, 99,585, 96,313.Median: 11.7, 10.0, 8.3, 9.0, 9.6 , 9.0 , 14.3, 8.7.Deficient %: (< 3.37) 2.5%, 4.0%, 7.0%, 5.9% , 4.7% , 3.4%, 2.2% , 6.7%.Intermediate %: (3.38 - 5.38) 6.4%, 10.2% , 15.4% , 13.2%, 11.4%, 11.8%, 4.7%, 15.0%.Normal %: (>5.38) 91%, 86%, 78%, 81%, 84%, 85% 93%, 78%.All ous lots: 287, 289, 291, 293, 295.N: 396,865, 339,741, 276,147, 299,971, 108,614.Median: 11.3, 12.4, 9.4 , 9.6, 8.7.Deficient % (< 3.37): 3.6% , 1.2%, 5.7% , 6.2%, 6.1%.Intermediate % (3.38 - 5.38) : 8.9%, 4.5%, 13.1%, 13.1%, 16.5%.Normal % (>5.38): 87%, 94%, 81%, 81%, 74%.Additionally, siemens performed a multi-lot technical study with 20 patient pools over 6 in-date reagent lots.Lot 289 recovers control and patient pool values higher relative to other lots but did not reproduce sample results changing from deficient to normal or normal to deficient.No product problem was identified.The instrument is performing within specifications.No further evaluation of the device is required.Siemens is exploring possible assay enhancements to reduce lot to lot variability.
|